Zydus announces Phase IV trial of Desidustat

30 Aug 2022 , 03:15 PM

Zydus Lifesciences Ltd. has announced the commencement of Phase IV clinical trial for Desidustat in patients with Chronic Kidney Disease (CKD) induced anemia

CKD is predicted to become one of the most common causes of premature death by 2040 globally. 

The Phase IV DREAM-CKD trial will enrol 1004 CKD patients in India, including 502 dialysis dependent, 502 dialysis independent CKD patients with anemia. 

This multicentre post marketing surveillance study will evaluate the safety of Desidustat for the treatment of anemia in subjects with chronic kidney disease over a period of 52 weeks, in addition to secondary endpoints including; change in hemoglobin level, change in Lipid profile including Small dense LDL, change in weight, change in VEGF, change in serum hepcidin and evaluation of safety laboratory parameters.

At around 3:15 PM, Zydus Lifesciences Ltd is currently trading at Rs378.10 per share up by Rs0.6 or 0.16% from its previous closing of Rs377.50 per share on the BSE.

For feedback and suggestions, write to us at [e-mail]